FETCH wins Venture Challenge Spring 2024!
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2024 spring edition is FETCH! The innovative startup has developed a groundbreaking approach for precision diagnostics in personalized medicine for metastatic cancer patients through tumor cell analysis from a large blood volume. This method can provide the crucial information needed to select the best targeted therapies, overcoming the limitations of traditional biopsies and current liquid biopsy methods.
The Venture Challenge Spring started in May and today at the Dutch Biotech Event. FETCH takes home the €25.000 prize money to invest in their growth. The other highly-motivated participating teams were: MaTiRex, Myonovum, QTM Biosciences, THRONCAT and Twente Medical Optics. QTM Biosciences is one of the tenants at Pivot Park.
“The Venture Challenge helped us to get clarity on the core of our unique value and potential. This will allow us to focus on our strengths, but also address the potential pitfalls we identified during the program. With this, we can take the next step in revolutionizing oncologic care.” – Michiel Stevens, founder of FETCH.
FETCH is initially focusing on metastatic prostate cancer and planning to broaden their application to other types of metastatic cancers. Their advanced immunomagnetic enrichment technique for circulating tumor cells (CTCs) from leukapheresis material is designed to be adaptable and scalable, which means it can potentially be applied to a wide range of cancers where current biopsy methods are impractical or insufficient. They are also looking to integrate their service into research programs. By doing so, FETCH is poised to contribute significantly to the field of personalized cancer treatment, offering a valuable tool for real-time tumor monitoring and targeted therapy selection.
Want to participate in the next venture challenge? Click here for more information. The call for the Venture Challenge Fall closes 2 July, 14:00 CEST, 2024! Apply here.